http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 17:25:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html si-local-file:///var/storage/secattach/20260311/26147293.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html Wed, 11 Mar 2026 17:25:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html si-local-file:///var/storage/secattach/20260311/26147293.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html Wed, 11 Mar 2026 17:25:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html si-local-file:///var/storage/secattach/20260311/26147293.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.+++++++++++++/26147293.html Wed, 11 Mar 2026 17:25:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html si-local-file:///var/storage/secattach/20260304/26111052.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html Wed, 04 Mar 2026 16:07:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html si-local-file:///var/storage/secattach/20260304/26111052.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html Wed, 04 Mar 2026 16:07:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html si-local-file:///var/storage/secattach/20260304/26111052.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Mar+02++Filed+by%3A+Putnam+Leah+R/26111052.html Wed, 04 Mar 2026 16:07:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html si-local-file:///var/storage/secattach/20260224/26052727.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html Tue, 24 Feb 2026 16:59:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html si-local-file:///var/storage/secattach/20260224/26052727.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html Tue, 24 Feb 2026 16:59:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html si-local-file:///var/storage/secattach/20260224/26052727.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Dec+31/26052727.html Tue, 24 Feb 2026 16:59:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/Analyst+PT+Change/Beyond+Inc+%28BBBY%29+PT+Lowered+at+Piper+Sandler%3B+%27Still+a+Lot+of+Uncertainty+Ahead%27/26047502.html <p>Piper Sandler analyst Peter J. Keith lowered the price target on Beyond Inc (NYSE: BBBY) to $8.00 (from $10.00) while maintaining a Neutral rating.</p><p>The analyst commented: "Showing Sequential Improvement; Still a Lot of Uncertainty Ahead; We reiterate our Neutral rating and lower our PT to $8 (0.3x 2027E Sales) following a Q4 print that showed sequential improvement in the core business. While revenue was still -10% Y/Y, internal initiatives - such as SKU consolidation - appear to be gaining traction. Mgmt. characterized 2025 as a trough year, targeting a return to topline growth in 2026 with +LSD to +MSD % http://www.streetinsider.com/Analyst+PT+Change/Beyond+Inc+%28BBBY%29+PT+Lowered+at+Piper+Sandler%3B+%27Still+a+Lot+of+Uncertainty+Ahead%27/26047502.html Tue, 24 Feb 2026 08:36:56 -0400 BBBY http://www.streetinsider.com/Analyst+Comments/Beyond+Inc+%28BBBY%29+PT+Lowered+at+Piper+Sandler%3B+%27Still+a+Lot+of+Uncertainty+Ahead%27/26047502.html <p>Piper Sandler analyst Peter J. Keith lowered the price target on Beyond Inc (NYSE: BBBY) to $8.00 (from $10.00) while maintaining a Neutral rating.</p><p>The analyst commented: "Showing Sequential Improvement; Still a Lot of Uncertainty Ahead; We reiterate our Neutral rating and lower our PT to $8 (0.3x 2027E Sales) following a Q4 print that showed sequential improvement in the core business. While revenue was still -10% Y/Y, internal initiatives - such as SKU consolidation - appear to be gaining traction. Mgmt. characterized 2025 as a trough year, targeting a return to topline growth in 2026 with +LSD to +MSD % http://www.streetinsider.com/Analyst+Comments/Beyond+Inc+%28BBBY%29+PT+Lowered+at+Piper+Sandler%3B+%27Still+a+Lot+of+Uncertainty+Ahead%27/26047502.html Tue, 24 Feb 2026 08:36:56 -0400 BBBY http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html <p><strong>After-hours movers: </strong></p><p><strong>Hims & Hers Health </strong>(NYSE: HIMS) fell 2% despite in-line quarterly results, after guidance for operating profit missed estimates. Hims sees 2026 Adjusted Ebitda of $300 million to $375 million, vs the estimate of $370.8 million. </p><p><strong>Bed Bath & Beyond</strong> (NYSE: BBBY) rose 3.7% after revenue beats estimates. Revenue for the quarter came in at $273.4 million versus the consensus estimate of $262.94 million.</p><p><strong>Myriad Genetics</strong> (NASDAQ: MYGN) rose 18% after reporting better than expected EPS and revenue for the final quarter of 2025.</p><p><strong>Keysight Technologies</strong> (NYSE: KEYS) rose 14% after results and guidance easily beat analysts' estimates. http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Hims+%26+Hers+Health%2C+Keysight%2C+Bed+Bath+%26+Beyond%2C+Myriad+Genetics%2C+and+more/26044148.html Mon, 23 Feb 2026 16:42:55 -0400 BBBY EVER HIMS KEYS KTOS MYGN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Feb+23/26043052.html si-local-file:///var/storage/secattach/20260223/26043052.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Feb+23/26043052.html Mon, 23 Feb 2026 16:04:00 -0400 BBBY BYON O.00007816 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Feb+23/26043052.html si-local-file:///var/storage/secattach/20260223/26043052.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BED+BATH+%26amp%3B+BEYOND%2C+INC.++For%3A+Feb+23/26043052.html Mon, 23 Feb 2026 16:04:00 -0400 BBBY BYON O.00007816